REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Pronged attack tested for Tough-to-Treat lymphoma that returns
Disease control Recruiting nowThis study is testing a new treatment sequence for adults whose aggressive large B-cell lymphoma has come back or didn't respond to initial therapy. Participants first receive two targeted drugs (tafasitamab and lenalidomide), followed by a stronger chemotherapy regimen. The main…
Matched conditions: REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New immune therapy trial aims to control Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing whether adding a new immune-boosting drug called epcoritamab to standard chemotherapy and a stem cell transplant can better control aggressive large B-cell lymphoma that has returned or not responded to prior treatment. It will involve about 25 adults whose …
Matched conditions: REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Poop pills trial aims to boost cancer treatment success
Disease control Recruiting nowThis study is testing whether taking capsules containing healthy donor stool (fecal microbiome transplant) can improve gut health and treatment outcomes for adults with hard-to-treat lymphoma. All participants receive standard CAR-T cell therapy, a powerful cancer treatment, but …
Matched conditions: REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New drug combo aims to boost Last-Resort cancer treatment
Disease control Recruiting nowThis study is testing whether adding a new drug called odronextamab can improve the effectiveness of a powerful last-resort treatment (CAR-T therapy) for an aggressive type of blood cancer called DLBCL. The trial is for adults whose cancer has come back or hasn't responded to at …
Matched conditions: REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC